immunate 500 iu fviii/375 iu vwf powder and solvent for solution for injection
takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 500 iu von willebrand factor, human 375 iu - antihemorrhagics
fanhdi 100 iuml 1500 iu (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1500 iu/dose - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
fanhdi 25 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a .fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
fanhdi 50 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
fanhdi 100 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1000 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
immunate 500iu+375iu powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii, von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 500iu+375iu
haemate p 1000 iu fviii 2400 iu vwf
csl behring ltd., israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection/infusion - factor viii (human) 1000 iu / 15 ml; von willebrand factor 2400 iu / 15 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia,prophylaxis during operation, von willebrands disease.
haemate p 250 iu fviii 600 iu vwf
csl behring ltd., israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection/infusion - factor viii (human) 250 iu / 5 ml; von willebrand factor 600 iu / 5 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia, prophylaxis during operation, von willebrand's disease.
dried factor viii fraction, type 8y
bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - factor viii, human - powder and solvent for solution for injection - factor viii, human 25 iu/ml - antihemorrhagics
voncento
csl behring gmbh - human coagulation factor viii, human von willebrand factor - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand disease (vwd)prophylaxis and treatment of haemorrhage or surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated.haemophilia a (congenital factor-viii deficiency)prophylaxis and treatment of bleeding in patients with haemophilia a.